Target Name: S100G
NCBI ID: G795
Review Report on S100G Target / Biomarker Content of Review Report on S100G Target / Biomarker
S100G
Other Name(s): S100 calcium-binding protein G | vitamin D-dependent calcium-binding protein, intestinal | calbindin D9K | OTTHUMP00000022988 | Calbindin-D9K | S100D | S100G_HUMAN | Calbindin D9K | Calbindin 3, (vitamin D-dependent calcium-binding protein) | Protein S100-G | CABP | CABP9K | CALB3 | calbindin-D9k | Calbindin-D9k | Vitamin D-dependent calcium-binding protein, intestinal | calbindin 3, (vitamin D-dependent calcium-binding protein) | CABP1 | MGC138379 | S100 calcium binding protein G

S100G: A Unique Protein Involved in Intracellular Signaling and Disease

S100G, or S100 calcium-binding protein G, is a protein that is expressed in various tissues throughout the body. It is a member of the S100 family of proteins, which are known for their ability to interact with calcium ions. S100G is unique among its family members because of its structure and function.

S100G is a 20kDa protein that is expressed in the brain, heart, skeletal muscles, and other tissues. It is highly localized to the cytoplasm and can be found in high concentrations in the brain. S100G is also known for its ability to interact with calcium ions, which is essential for many cellular processes.

One of the key functions of S100G is its role in intracellular signaling. It is involved in a variety of signaling pathways, including the regulation of ion channels, protein kinase, and transcription factors. S100G has been shown to play a critical role in the regulation of muscle contractions and to influence the structure and function of neural circuits.

In addition to its role in intracellular signaling, S100G is also thought to have potential as a drug target or biomarker. Its ability to interact with calcium ions and its unique structure have led to the possibility that it may be a useful target for small molecule inhibitors.

S100G has also been shown to be involved in the regulation of cellular processes that are important for many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that S100G is involved in the regulation of cell division, apoptosis, and inflammation.

The potential drug targeting of S100G is based on its ability to interact with calcium ions and its unique structure. Calcium ions are essential for many cellular processes, including muscle contractions, neural signaling, and cell division. By inhibiting the activity of S100G, researchers may be able to disrupt these processes and cause a range of cellular changes.

In addition to its potential as a drug target, S100G is also a potential biomarker for a variety of diseases. Its unique structure and function make it an attractive candidate for use as a diagnostic or diagnostic biomarker. For example, studies have shown that S100G is Highly expressed in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that S100G may be a useful biomarker for these diseases.

In conclusion, S100G is a unique and complex protein that is involved in a variety of cellular processes throughout the body. Its ability to interact with calcium ions and its unique structure make it an attractive candidate for potential drug targeting and biomarker development. Further research is needed to fully understand the role of S100G in cellular processes and its potential as a drug target or biomarker.

Protein Name: S100 Calcium Binding Protein G

The "S100G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS | SACS-AS1 | SAE1 | SAFB | SAFB2 | SAG | SAGA complex | SAGE1 | SALL1 | SALL2 | SALL3 | SALL4 | SALL4P7 | SALRNA2 | SAMD1 | SAMD10 | SAMD11 | SAMD12 | SAMD12-AS1 | SAMD13 | SAMD14 | SAMD15 | SAMD3 | SAMD4A | SAMD4A-AS1 | SAMD4B | SAMD5 | SAMD7 | SAMD8 | SAMD9 | SAMD9L | SAMHD1 | SAMM50 | SAMMSON | SAMSN1 | SAMSN1-AS1 | SANBR | SAP130 | SAP18 | SAP30 | SAP30-DT | SAP30BP | SAP30L | SAP30L-AS1 | SAPCD1 | SAPCD1-AS1 | SAPCD2 | SAR1A | SAR1B | SARAF | SARDH | SARM1 | SARNP | SARS1 | SARS2 | SART1 | SART3 | SASH1 | SASH3 | SASS6 | SAT1 | SAT1-DT | SAT2 | SATB1 | SATB1-AS1 | SATB2 | SATB2-AS1 | SATL1 | SAV1 | SAXO1 | SAXO2 | SAYSD1 | SBDS | SBDSP1 | SBF1 | SBF1P1 | SBF2 | SBF2-AS1 | SBK1 | SBK2 | SBK3 | SBNO1 | SBNO2